Hubbry Logo
ThrombectomyThrombectomyMain
Open search
Thrombectomy
Community hub
Thrombectomy
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Thrombectomy
Thrombectomy
Thrombectomy
View on Wikipedia
from Wikipedia

Mechanical thrombectomy, or simply thrombectomy, is the removal of a blood clot (thrombus) from a blood vessel, often and especially endovascularly as an interventional radiology procedure called endovascular thrombectomy (EVT). It thus contrasts with thrombolysis (clot dissolution) by thrombolytic medications (e.g., alteplase, reteplase), as either alternative or complement thereto. It is commonly performed in the cerebral arteries (interventional neuroradiology) as treatment to reverse the ischemia in some ischemic strokes (i.e., those in which the blockage is a suitable candidate for such retrieval). Open vascular surgery versions of thrombectomy also exist. The effectiveness of thrombectomy for strokes was confirmed in several randomised clinical trials conducted at various medical centers throughout the United States, as reported in a seminal multistudy report in 2015.[1]

Applications in brain

[edit]

Ischemic stroke represents the fifth most common cause of death in the western world and the number one cause of long-term disability. Until recent times, systemic intravenous fibrinolysis was the only evidence-based therapy for patients with acute onset of stroke due to large vessel occlusion.

History

[edit]

The world's first thrombectomy (in case of blood clot in the brain) was performed in 1994 at Sahlgrenska University Hospital, Gothenburg, Sweden by senior physician Gunnar Wikholm.[2][3]

In 2015, the results of five trials from different countries were published in the New England Journal of Medicine, demonstrating the safety and efficacy of mechanical thrombectomy with stent-retrievers in improving outcomes and reducing mortality for patients who present within six hours from their time last known well. It is now a widespread procedure performed in many hospitals around the globe, especially comprehensive stroke centers, although many other hospitals are not yet able to supply the service enough to meet the need.[4] Large obstacles to making EVT more widely available are both systematic hurdles at the prehospital stages[4] and the intrahospital barrier of a scarcity of interventional neuroradiologists.[4][5] They concern TTR (time to reperfusion), which is the same underlying problem as the golden hour in general, albeit several hours in the case of TTR: that is, EVT performed within 2 or 3 hours can help vastly, whereas EVT performed after 6 to 12 hours is often (although not always) too late to prevent the permanent sequelae of the ischemia.[4] In this respect, the dissemination of EVT into clinical practice shows how translational medicine has various layers, some easier to solve and some harder: it was in some respects straightforward to develop the technology of EVT in the 2000s and 2010s (that is, the catheter tips and procedures),[4] but it is not easy to revamp the standard of care in prehospital settings (such as awareness among family members and bystanders, optimal techniques for emergency medical services, and so on),[4] which deployment of timely EVT requires.[4]

In 2018 the DAWN and DEFUSE-3 trials were published. These trials showed that mechanical thrombectomy is a safe and effective treatment for individuals who have an acute ischemic stroke, even (in some cases) out to 24 hours after symptom onset.[6][7] Most studies, however, have focused on thrombectomies in anterior circulation strokes. In recent years, increasing evidence on the efficacy of mechanical thrombectomy in posterior circulation strokes has been published.[8]

Stent-retriever thrombectomy

[edit]

The procedure can be performed with general anesthesia or under conscious sedation in an angiographic room. A system of coaxial catheters is pushed inside the arterial circulation, usually through a percutaneous access to the right femoral artery. A microcatheter is finally positioned beyond the occluded segment and a stent-retriever is deployed to catch the thrombus; finally, the stent is pulled out from the artery, usually under continuous aspiration in the larger catheters.[citation needed]

Direct aspiration

[edit]

A different technique for mechanical thrombectomy in the brain is direct aspiration. It is performed by pushing a large soft aspiration catheter into the occluded vessel and applying direct aspiration to retrieve the thrombus; it can be combined with the stent-retriever technique to achieve higher recanalization rates, but the complexity of the procedure increases.[citation needed]

Direct aspiration has not been studied as thoroughly as stent-retriever thrombectomy, but it is still widely performed because of its relative simplicity and low cost.[citation needed]

Delivery

[edit]

Patients in London who suffered stroke were found to be much more likely to get thrombectomy in 2022 than those in other parts of England. 42% of thrombectomy units only operated during office hours and Monday to Friday, largely due to a shortage of neurointerventionalists.[5]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Thrombectomy

View on Grokipedia
from Grokipedia
Thrombectomy is a minimally invasive endovascular procedure that mechanically removes thrombi— clots—from obstructed vessels under guidance, restoring flow and mitigating tissue damage. Primarily applied to acute ischemic resulting from large vessel occlusion, it targets to salvage tissue at risk, with techniques involving catheter-based aspiration or stent-retriever devices. The procedure has also been adapted for conditions such as and deep vein thrombosis, though its most transformative impact lies in intervention. The evolution of thrombectomy traces from early intra-arterial attempts in the 1990s to mechanical devices like the MERCI retriever approved in 2004, but widespread adoption followed landmark randomized controlled trials in 2015—such as , , and EXTEND-IA—which established its superiority over intravenous alone for eligible patients, yielding higher rates of functional independence ( score of 0-2 at 90 days) with number-needed-to-treat as low as 2.6 in some cohorts. These trials, involving over 1,200 patients across multiple centers, demonstrated recanalization rates exceeding 70% and reduced mortality, shifting guidelines to recommend thrombectomy as standard care within 6-24 hours for select cases with favorable imaging profiles like perfusion mismatch. Subsequent studies extended efficacy to large-core infarcts and extended time windows, underscoring causal links between rapid reperfusion and via empirical outcome data. Despite its efficacy, thrombectomy faces challenges including procedural risks like vessel perforation (1-2% incidence) and hemorrhage, debates over strategies—where general may impair outcomes compared to conscious in observational data—and disparities in access due to specialized infrastructure requirements, limiting real-world implementation to under 10% of eligible patients globally. Ongoing refinements in device technology and patient selection algorithms, informed by meta-analyses of over 10,000 cases, continue to optimize first-pass success rates above 80%, though gaps persist for pediatric applications and ultra-large vessel occlusions. These factors highlight thrombectomy's role as a high-stakes intervention grounded in rigorous , balancing substantial benefits against logistical and biological constraints.

Definition and Fundamentals

Procedure Description

Endovascular thrombectomy is a minimally invasive interventional procedure designed to mechanically remove thrombi obstructing , primarily in cases of acute ischemic caused by large vessel occlusion. Performed under fluoroscopic guidance in a , it involves vascular access, typically via the common in the , where a sheath is inserted to facilitate introduction. with conscious sedation is standard, allowing real-time neurological assessment during the intervention. The procedure commences with diagnostic to confirm the occlusion site and extent, often following initial non-contrast CT or for patient selection. A guide is advanced over a 0.035-inch guidewire to the proximal target vessel, such as the internal carotid or . A smaller microcatheter (0.017–0.021 inch) and microwire (0.014–0.016 inch) are then navigated through the to a position distal to the occlusion, enabling precise device delivery. Thrombus retrieval employs devices such as stent retrievers or aspiration catheters. In stent-retriever methods, the retriever (e.g., a self-expanding nitinol mesh like Solitaire) is deployed from the microcatheter, allowed to expand and integrate with the clot for 3–5 minutes, then withdrawn under continuous proximal aspiration via the guide catheter to minimize embolization. Direct aspiration techniques position a large-bore catheter (e.g., 6–8 French) at the thrombus face and apply manual or pump-generated negative pressure to suction the material, often as a first-line or adjunctive approach (e.g., ADAPT: A Direct Aspiration First Pass Technique). Multiple passes may be required, with post-retrieval angiography assessing reperfusion via the Thrombolysis in Cerebral Infarction (TICI) scale, targeting grades 2b–3 for near-complete or full flow restoration. The intervention typically lasts 60–120 minutes, influenced by occlusion location, thrombus burden, and vascular anatomy. Hemodynamic support, including balloon occlusion or temporary flow arrest, may be used to enhance safety during retrieval. Upon completion, the access site is closed with manual compression or closure devices, followed by intensive care monitoring for reperfusion-related complications such as hemorrhage or edema.

Physiological Rationale

Thrombectomy addresses acute ischemic by mechanically extracting occlusive thrombi from large cerebral vessels, thereby restoring antegrade cerebral blood flow (CBF) to ischemic regions. In large vessel occlusion (LVO), the impedes , leading to rapid onset of hypoxia and nutrient deprivation in downstream , which initiates a cascade of cellular injury including ATP depletion, ionic imbalance, , and . The ischemic territory comprises an infarct core—where CBF falls below 10-12 mL/100g/min, rendering tissue irreversibly damaged within minutes—and a surrounding penumbra, where CBF is reduced to 10-20 mL/100g/min but maintained above the viability threshold via collateral circulation, allowing delayed neuronal death if reperfusion is not achieved. The core physiological benefit of thrombectomy lies in salvaging this penumbra by achieving rapid recanalization, which elevates CBF to levels sufficient to halt progression to and mitigate secondary injury mechanisms such as reperfusion-induced and . Unlike intravenous , which relies on pharmacological dissolution and may fail in dense clots, mechanical removal ensures high rates of substantial reperfusion (e.g., modified in score ≥2b), directly countering the time-dependent expansion of the infarct core into penumbral zones. Studies confirm that penumbral preservation correlates with improved functional outcomes, as timely restoration of preserves neuronal integrity and metabolic in collateral-dependent regions. This rationale extends from first-principles of and oxygen delivery: normal gray matter requires CBF >20 mL/100g/min for electrophysiological function and >55 mL/100g/min for protein synthesis; thrombectomy-induced reperfusion exceeds these thresholds in viable tissue, averting oligemia-induced dysfunction while minimizing risks like hemorrhage in already necrotic core areas. In non-cerebral applications, such as peripheral , the principle similarly hinges on reversing limb- or organ-threatening ischemia by clot extraction, though cerebral efficacy is uniquely tied to the brain's intolerance for even brief hypoperfusion due to high metabolic demand and limited collaterals in some patients.

Historical Development

Early Attempts and Pre-Endovascular Era

Surgical thrombectomy for acute ischemic emerged in the mid-20th century as an attempt to mechanically restore blood flow in large cerebral vessel occlusions, predating catheter-based endovascular methods. The inaugural procedure targeted the (MCA), with E. Craig Welch reporting the first successful in 1957, involving temporary vessel occlusion via , arteriotomy, and manual clot extraction using forceps or suction under direct visualization. This approach built on earlier peripheral arterial embolectomies but faced unique challenges in intracranial vessels, including limited surgical access and the fragility of . Initial cases demonstrated technical feasibility in restoring patency, yet reliance on clinical symptoms alone for diagnosis—without computed tomography or —often delayed intervention, exacerbating ischemic damage. Subsequent advancements incorporated microsurgical techniques in the 1960s, enhancing precision during clot removal. Jacobson et al. described an MCA embolectomy in 1962, emphasizing the use of operating microscopes to minimize endothelial trauma and ischemia time during clamping, which typically lasted 10-20 minutes. For proximal (ICA) occlusions, surgical exposure via cervical incision proved more straightforward, with Meyer et al. reporting successful in 1962, achieving recanalization through assistance or direct extraction. Pioneers like M. Gazi Yasargil further refined intracranial procedures, performing early microvascular embolectomies that integrated magnification and finer instrumentation, though these remained experimental and case-specific. Despite technical successes in small series, outcomes were generally poor due to inherent limitations: most patients presented beyond 6 hours from symptom onset, when irreversible had occurred, and procedures carried risks of reperfusion hemorrhage, vessel spasm, and perioperative extension. Pre-1990 reports documented recanalization in 50-70% of attempted cases, but mortality rates approached 40% and favorable functional recovery (e.g., 0-2) occurred in under 30%, underscoring the method's selectivity for young patients with minimal comorbidities and embolic rather than thrombotic occlusions. Surgical thus served as a proof-of-concept for mechanical but waned in favor as improved diagnosis and non-invasive therapies like intravenous gained traction, relegating open techniques to rare, adjunctive roles in the pre-endovascular landscape.

Endovascular Era and Pivotal Trials

The endovascular era of mechanical thrombectomy for acute ischemic stroke emerged in the mid-2010s, driven by refinements in stent-retriever technology and improved patient selection via advanced imaging, which addressed limitations of prior trials using first-generation devices like the Merci retriever. Earlier multicenter randomized controlled trials, such as IMS III (published 2013), had failed to demonstrate superiority of intra-arterial therapy over intravenous alone, with neutral functional outcomes attributed to delayed treatment times, suboptimal reperfusion rates, and inclusion of heterogeneous occlusions. In contrast, subsequent studies leveraged retrievable stents (e.g., Solitaire FR) for higher recanalization success (often >80%) and emphasized proximal anterior circulation large-vessel occlusions with salvageable penumral tissue. The landmark Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the (MR CLEAN), published December 17, 2014, provided the first robust evidence of benefit. This phase 3, multicenter trial randomized 500 patients with proximal intracranial arterial occlusion (internal carotid or ) within 6 hours of onset to intra-arterial treatment plus standard care versus standard care alone; 89% of the intervention group received intravenous if eligible. The primary outcome was (mRS) score at 90 days, with the intervention group showing a shift toward better outcomes (common 1.67, 95% CI 1.21-2.30; P<0.001), including 32.6% achieving mRS 0-2 versus 19.1% in controls. Two-year follow-up confirmed sustained benefits, with reduced mortality and disability. Building on MR CLEAN, four pivotal trials published in 2015—ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT—replicated and extended these results in more rigorously selected cohorts, focusing on rapid intervention (median door-to-groin times <90 minutes) and imaging criteria like Alberta Stroke Program Early CT Score (ASPECTS) ≥6 or perfusion mismatch to identify small infarct cores with favorable collaterals. The ESCAPE trial (Randomized Assessment of Rapid Endovascular Treatment of Acute Stroke), reported February 11, 2015, enrolled 237 patients with small-core infarcts and good collaterals within 12 hours; endovascular therapy yielded 53% mRS 0-2 at 90 days versus 29% with medical management (odds ratio 4.40, 95% CI 2.61-7.40; P<0.001), alongside reduced mortality (10.4% vs. 19.0%). EXTEND-IA reported 71% mRS 0-2 with thrombectomy versus 40% controls (RR 2.6, 95% CI 1.2-5.6; P=0.01), SWIFT PRIME showed 60% versus 35% (OR 5.1, 95% CI 2.8-9.3), and REVASCAT 44% versus 28% (aOR 2.1, 95% CI 1.1-4.0), all using stent retrievers primarily.
TrialPublication DateSample SizeTime WindowKey Selection/MethodPrimary Outcome (mRS 0-2 at 90 days)
MR CLEANDec 2014500≤6 hoursProximal occlusion; stent retriever ± IA tPA33% vs. 19% (OR 1.67)
ESCAPEFeb 2015237≤12 hoursGood collaterals/small core; rapid EVT53% vs. 29% (OR 4.40)
EXTEND-IAFeb 201570≤6 hoursPerfusion mismatch; stent retriever71% vs. 40% (RR 2.6)
SWIFT PRIMEJun 2015196≤6 hoursASPECTS ≥6; stent retriever60% vs. 35% (OR 5.1)
REVASCATJun 2015206≤8 hoursProximal occlusion; stent retriever44% vs. 28% (aOR 2.1)
These trials collectively established endovascular thrombectomy as a class I recommendation for eligible patients, with number needed to treat of 6-8 for one additional independent outcome, prompting global reorganization of stroke systems toward thrombectomy-capable centers despite logistical challenges like transfer delays.

Endovascular Techniques

Stent-Retriever Methods

Stent-retriever methods employ self-expanding nitinol mesh devices delivered endovascularly to engage and extract occlusive thrombi, primarily in large-vessel acute ischemic stroke. These second- and third-generation devices, such as Solitaire (Medtronic) and Trevo (Stryker), feature laser-cut or braided structures with closed- or open-cell designs that provide radial force for vessel wall apposition and clot integration. The mechanism involves advancing a microcatheter and microwire across the thrombus under fluoroscopic guidance, followed by deployment of the compressed stent-retriever distal to the occlusion. Upon release, the device expands to diameters matching the vessel (typically 3-6 mm), exerting chronic outward force (approximately 0.01 N/mm) to embed into the thrombus, often slicing through fibrin-rich components and restoring 33-50% of baseline antegrade flow within seconds. Clot-device integration occurs over 3-5 minutes via mechanical interlocking and potential adhesive forces from thrombus deformation, enabling retrieval as a unit. Retrieval proceeds by slowly withdrawing the integrated assembly into a proximal guide catheter (positioned in the cervical internal carotid artery), frequently augmented by manual aspiration through the guide or a balloon guide catheter (BGC) for temporary flow arrest, which reduces distal embolization risk by 21-57%. First-pass recanalization rates reach 72-89% with these devices, outperforming earlier retrieval systems like MERCI (48-58%). Clinical efficacy is evidenced by pivotal trials such as MR CLEAN (2015), where stent-retriever use yielded 32.6% good functional outcomes (modified Rankin Scale ≤2 at 90 days) versus 19.1% with medical therapy alone, with recanalization in 58.7% of cases. Similar benefits appeared in ESCAPE and SWIFT PRIME, attributing success to immediate reperfusion minimizing ischemic penumbra expansion. Device variations, including dual-layer designs like EmboTrap, aim to enhance first-pass effects (up to 84.6% recanalization), though comparative superiority remains under evaluation in ongoing studies. For refractory occlusions, techniques like double stent-retriever deployment or combined "Solumbra" (stent-retriever plus direct aspiration) improve success, with the latter achieving 83.6% reperfusion in registries. BGC use further boosts outcomes, increasing favorable 90-day modified Rankin Scale scores by up to 30%. Limitations include procedure times of 20-40 minutes and dependency on clot composition, with fibrin-rich thrombi resisting integration in 20% of cases.

Direct Aspiration Approaches

Direct aspiration thrombectomy entails advancing a large-bore aspiration catheter to the proximal face of an intracranial thrombus and applying continuous negative pressure via a dedicated pump to achieve en bloc clot retrieval, often without initial reliance on stent retrievers. This approach leverages the thrombus's adherence to the vessel wall under suction, aiming for rapid revascularization in acute ischemic stroke due to large vessel occlusion. Unlike stent-retriever methods, direct aspiration minimizes device manipulation within the vessel, potentially reducing endothelial trauma and procedural time. The A Direct Aspiration first Pass Technique (ADAPT), first described in 2013, exemplifies this strategy as a frontline intervention, employing aspiration alone for initial clot removal and reserving stent retrievers for rescue if needed. In ADAPT protocols, a 0.068- to 0.070-inch inner diameter catheter is navigated over a microwire to the occlusion site, with suction initiated to collapse the vessel distally and extract the thrombus. Commercial systems, such as the Penumbra System with ACE or JET reperfusion catheters connected to an aspiration pump, facilitate this by providing consistent vacuum levels up to -28 inHg, enabling retrieval of clots in anterior circulation occlusions like the middle cerebral artery. Evolving catheter designs, including those with distal access and flexible tips, have improved navigability and first-pass efficacy, with reported successful reperfusion rates after a single aspiration pass reaching 53-60% in internal carotid or M1 segment cases. Clinical evidence supports ADAPT's noninferiority to stent-retriever thrombectomy, with 90-day functional independence (modified Rankin Scale 0-2) rates of approximately 50-60% in eligible patients, alongside high recanalization (TICI 2b-3) in 70-95% overall. A first-pass effect—complete recanalization on the initial attempt—occurs in over 55% of cases and correlates with improved outcomes, including lower symptomatic intracranial hemorrhage rates (around 5%) compared to multi-pass or combined techniques. Direct aspiration also demonstrates cost-effectiveness, reducing procedural expenses by about $5,000 per case through fewer consumables, without compromising reperfusion (achieved in 94.6% of patients across 1.9 median passes). In scenarios of aspiration failure (e.g., fragmented or adherent clots), adjunctive stent deployment or balloon angioplasty yields rescue success in most instances, underscoring the technique's role as a foundational step. Predictors of aspiration success include thrombus location in M1-M2 segments, smaller clot burden, and absence of calcification, with failure more common in distal or posterior circulations requiring technique adaptation.

Combined and Adjunctive Strategies

Combined mechanical techniques integrate contact aspiration with stent-retriever deployment to optimize clot engagement and removal, particularly for large-vessel occlusions in acute ischemic stroke. In this approach, a stent retriever is deployed to capture the proximal thrombus while simultaneous aspiration through a large-bore catheter addresses distal fragments or adherent clot material, potentially reducing embolization and improving immediate recanalization. Meta-analyses of observational data indicate that combined aspiration and stent-retriever methods yield superior first-pass reperfusion rates compared to stent-retriever monotherapy, with successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2b) achieved in up to 70-80% of cases in some series. Randomized trials, however, have produced mixed results on overall efficacy. The ASTER trial, involving 408 patients with anterior circulation large-vessel occlusion, found that initial combined contact aspiration and stent-retriever thrombectomy did not significantly increase the rate of near-total or total reperfusion (expanded TICI [eTICI] 2c/3: 64.5% vs. 57.9%; adjusted odds ratio 1.33, 95% CI 0.88-1.99) compared to stent-retriever alone, though initial successful reperfusion (eTICI ≥2b after first pass) was higher (86.2% vs. 72.3%). Functional independence at 90 days (modified Rankin Scale [mRS] 0-2) was similar between groups (38.0% vs. 41.9%), with the combined approach associated with fewer parenchymal hematomas type 2 (3.1% vs. 8.6%). Subsequent analyses suggest combined techniques may benefit specific subgroups, such as posterior circulation occlusions, where first-line combined approaches improved recanalization in observational cohorts. Adjunctive pharmacological strategies aim to mitigate microvascular thrombosis or incomplete reperfusion following mechanical , often targeting residual distal emboli. Intra-arterial thrombolysis (IAT) with agents like alteplase or urokinase after endovascular therapy has demonstrated improved excellent functional outcomes (mRS 0-1 at 90 days) in patients with successful but suboptimal reperfusion, as evidenced by the CHOICE trial, which reported enhanced recovery without a significant increase in symptomatic intracranial hemorrhage. Ongoing trials, such as POST-UK evaluating intra-arterial urokinase post-, continue to assess safety and efficacy in large-vessel occlusion, with preliminary data suggesting potential quality-of-life benefits. Intra-arterial antithrombotic therapy during , including glycoprotein IIb/IIIa inhibitors like tirofiban or eptifibatide, seeks to promote microvascular reperfusion but carries elevated hemorrhage risks without consistent functional gains; the MR CLEAN-MED trial found increased symptomatic intracranial hemorrhage with periprocedural heparin and aspirin. Intravenous thrombolysis prior to (bridge therapy) remains standard for eligible patients, with trials confirming its safety and potential synergy in extending treatment windows up to 4.5 hours from onset. Emerging adjuncts, such as normobaric hyperoxia or neuroprotectants like nerinetide, show promise in reducing infarct volume or improving outcomes in non-thrombolysis cohorts but require further validation. Overall, adjunctive use is reserved for incomplete recanalization cases due to hemorrhagic risks, with selection guided by reperfusion grades and patient factors.

Clinical Applications

Acute Ischemic Stroke

Endovascular thrombectomy is the standard of care for acute ischemic stroke due to large vessel occlusion (LVO) in the anterior circulation, targeting thrombi in the intracranial internal carotid artery or middle cerebral artery M1 segment to restore perfusion and mitigate infarct progression. Eligible patients typically present with a National Institutes of Health Stroke Scale (NIHSS) score of 6 or higher, Alberta Stroke Program Early CT Score (ASPECTS) of 6 or greater on non-contrast CT to indicate limited early infarct, and minimal prestroke disability (modified Rankin Scale [mRS] score 0-1). Confirmation of LVO via CT angiography or magnetic resonance angiography is required, with the procedure often combined with intravenous alteplase if initiated within 4.5 hours of symptom onset and no contraindications exist. In the early time window (0-6 hours from last known well), American Heart Association/American Stroke Association (AHA/ASA) guidelines provide class I recommendation for thrombectomy in patients meeting imaging and clinical criteria, independent of thrombolysis eligibility, due to superior recanalization rates over medical management alone. For the extended window (6-24 hours), patient selection incorporates advanced imaging such as CT perfusion or MRI to demonstrate favorable mismatch profiles—small core infarct (e.g., <70 mL in patients under 80 years or <100 mL in older patients with lower NIHSS) relative to hypoperfused tissue—aligning with criteria from trials validating efficacy beyond traditional timelines. Application extends to posterior circulation LVO, including basilar artery occlusion, where thrombectomy is recommended up to 24 hours in select cases with viable brainstem tissue on imaging, reflecting improved survival and functional outcomes compared to anticoagulation or thrombolysis. Recent expansions include patients with larger infarct cores (ASPECTS 2-5 or core volumes 50-100 mL), where 2025 AHA guidelines endorse thrombectomy based on randomized evidence showing net benefit despite higher periprocedural risks. Clinical outcomes demonstrate thrombectomy's efficacy, with meta-analyses of trials in LVO stroke reporting odds ratios of 2.0 to 2.5 for achieving functional independence (mRS 0-2 at 90 days) versus best medical management, translating to 20-30 additional independent patients per 100 treated in eligible cohorts. Long-term follow-up confirms sustained benefits, including reduced mortality and disability, particularly when reperfusion is achieved early in the procedure (e.g., extended Thrombolysis in Cerebral Infarction score 2b-3). Transfer protocols to comprehensive stroke centers are emphasized to minimize door-to-groin puncture times, targeting under 90 minutes for direct arrivals and 60 minutes for drips-and-ships.

Peripheral and Pulmonary Indications

Thrombectomy in peripheral vascular disease is primarily indicated for acute limb ischemia (ALI) resulting from arterial thromboembolism, where rapid restoration of blood flow is essential to salvage limb viability and prevent amputation. According to Rutherford classification, catheter-based thrombolysis or mechanical thrombectomy may be considered for category IIb ALI of greater than 14 days' duration, particularly when surgical options are limited or contraindicated. Devices such as the Indigo Aspiration System have demonstrated safety and efficacy in treating lower extremity arterial occlusions, with technical success rates exceeding 90% in observational studies involving patients with Rutherford IIa-III ischemia, achieving limb salvage in most cases while minimizing distal embolization risks through continuous aspiration. Mechanical thrombectomy using rotational devices like Rotarex has been evaluated in acute and subacute occlusions, showing patency restoration in up to 88% of cases across 16 clinical studies, though evidence remains largely from non-randomized data emphasizing its role in reducing thrombolytic-related bleeding compared to pharmacomechanical approaches. The 2024 ACC/AHA guidelines for lower extremity peripheral artery disease endorse endovascular revascularization, including thrombectomy, for symptomatic ALI, prioritizing it in patients with viable or marginally threatened limbs to optimize outcomes over open surgery. In pulmonary embolism (PE), mechanical thrombectomy serves as an interventional option for high-risk cases with hemodynamic instability, such as massive PE causing shock or cardiac arrest, where systemic thrombolysis is contraindicated, ineffective, or carries excessive bleeding risk. The 2019 ESC guidelines recommend catheter-directed therapies, including aspiration thrombectomy, for high-risk PE when thrombolysis fails or is contraindicated, with recent updates elevating standalone aspiration thrombectomy to a class I indication for such patients due to its ability to rapidly reduce right ventricular strain without adjunctive fibrinolysis. Suction thrombectomy using large-bore catheters has shown hemodynamic improvements in intermediate- and high-risk PE, with procedural success rates of 90-100% in reducing pulmonary artery pressure and right ventricular/left ventricular ratio, as evidenced in multicenter registries and the PEERLESS trial, which compared large-bore mechanical thrombectomy to catheter-directed thrombolysis in 550 intermediate-risk patients, demonstrating noninferiority in clinical outcomes with fewer 30-day readmissions (3.2% vs. 7.9%). Catheter-directed thrombectomy without thrombolysis further supports efficacy in meta-analyses, yielding favorable safety profiles with major bleeding rates below 2% and mortality reductions in acute PE cohorts. These approaches are particularly valuable in submassive PE with right ventricular dysfunction, offering a bridge to recovery when anticoagulation alone is insufficient.

Evidence of Efficacy

Randomized Controlled Trials

The pivotal randomized controlled trials establishing the efficacy of endovascular for acute ischemic stroke with large vessel occlusion were conducted primarily between 2014 and 2015, demonstrating superior functional outcomes compared to intravenous thrombolysis alone or best medical management. The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), published in December 2014, was the first to show a significant benefit, with 232 patients randomized to intra-arterial treatment plus usual care versus usual care alone; the adjusted common odds ratio for improved modified Rankin Scale (mRS) score at 90 days was 1.67 (95% CI, 1.21-2.30), indicating higher rates of functional independence (32.6% vs. 19.1%). This trial included patients with proximal anterior circulation occlusion confirmed by CT angiography, treated within 6 hours of symptom onset, and used various thrombectomy devices. Concurrent trials reinforced these findings using advanced imaging for patient selection and stent-retriever technology. The Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) trial, stopped early for efficacy in 2015, enrolled 316 patients across 22 centers, randomizing them to rapid endovascular therapy or standard care; at 90 days, the adjusted common odds ratio for mRS shift was 2.26 (95% CI, 1.39-3.68), with 53% achieving functional independence (mRS 0-2) in the intervention group versus 29% in controls. Similarly, the Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial (EXTEND-IA) trial, also in 2015, used perfusion imaging to select 70 patients with small ischemic cores and mismatch; reperfusion rates were higher (86% vs. 49%), and the mRS odds ratio was 2.6 (95% CI, 1.0-6.5), though limited by small sample size. The Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment (SWIFT PRIME) trial, reported in 2015, randomized 196 patients post-thrombolysis to stent-retriever thrombectomy or t-PA alone, yielding a 60% rate of mRS 0-2 at 90 days versus 35% (OR 5.1, 95% CI 2.5-10.6). Pooled analyses of these early trials confirmed consistent benefits, with an overall number needed to treat of about 8 for one additional patient achieving functional independence, alongside acceptable safety profiles including symptomatic intracranial hemorrhage rates of 6-7%. Subsequent RCTs expanded indications to later time windows (up to 24 hours) and larger infarct cores, such as DAWN and DEFUSE 3 in 2018, which used mismatch criteria and showed mRS benefits (e.g., DAWN: 49% vs. 13% mRS 0-2; OR 2.77, 95% CI 1.60-4.80). More recent trials for large-core strokes (e.g., SELECT2, RESCUE-Japan LIMIT in 2023-2024) further validated efficacy, with meta-analyses reporting improved 90-day mRS (OR 1.53-2.0) and reduced mortality despite higher baseline risks.
TrialYearKey EligibilityPrimary Outcome (90-day mRS)Key Result
MR CLEAN2014LVO within 6h, ASPECTS ≥2Shift in mRSOR 1.67 (95% CI 1.21-2.30); 32.6% vs. 19.1% mRS 0-2
ESCAPE2015LVO with good collaterals, within 12hShift in mRSOR 2.26 (95% CI 1.39-3.68); 53% vs. 29% mRS 0-2
EXTEND-IA2015Perfusion mismatch, within 4.5h post-tPAShift in mRSOR 2.6 (95% CI 1.0-6.5); 71% vs. 40% mRS 0-2
SWIFT PRIME2015LVO post-tPA, within 6hRate of mRS 0-260% vs. 35%; OR 5.1 (95% CI 2.5-10.6)
These trials collectively shifted clinical guidelines toward routine thrombectomy in eligible patients, though efficacy depends on rapid intervention, operator experience, and precise imaging selection to mitigate risks like hemorrhage.

Selection Criteria and Predictors of Success

Selection for mechanical thrombectomy in acute ischemic stroke emphasizes patients with confirmed large vessel occlusion (LVO) in the anterior circulation, particularly the internal carotid artery or middle cerebral artery M1 segment, identified via computed tomography angiography (CTA) or magnetic resonance angiography (MRA). American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend thrombectomy as class I for patients presenting within 6 hours of last known normal with National Institutes of Health Stroke Scale (NIHSS) score ≥6, Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on non-contrast CT to exclude extensive early ischemia, and pretreatment modified Rankin Scale (mRS) score of 0-1 indicating functional independence. In the 6- to 24-hour window, selection relies on advanced imaging from the DAWN and DEFUSE 3 trials, targeting patients with LVO, small infarct core (e.g., <70 mL by automated software or <1.8 mL mismatch ratio), and favorable clinical-infarct mismatch or perfusion mismatch indicating salvageable penumbra, yielding class I recommendation despite higher baseline deficits. For posterior circulation, particularly basilar artery occlusion, thrombectomy is class I within 6 hours if LVO and salvageable tissue are confirmed, with class IIa extension beyond 6 hours based on imaging evidence of penumbra. Contraindications include extensive baseline infarction (ASPECTS <6), hemorrhage, or comorbidities precluding safe intervention, prioritizing multimodal imaging to refine eligibility and minimize futile procedures. Predictors of successful outcomes, defined as good functional recovery (mRS 0-2 at 90 days), include achievement of substantial reperfusion graded extended Thrombolysis in Cerebral Infarction (eTICI) 2b-3, which independently associates with higher rates of independence across trials. Shorter times from symptom onset to reperfusion (e.g., <300 minutes in early windows) and from door to groin puncture enhance efficacy, with each hour delay reducing odds of favorable outcome by approximately 10-20% in observational data. Patient factors favoring success encompass younger age (<70 years), lower pre-stroke mRS (0-2), and absence of severe comorbidities like atrial fibrillation or diabetes, while early neurological improvement post-procedure signals better 90-day prognosis and lower mortality. Imaging predictors include smaller baseline core infarct volume (<30 mL), robust collateral circulation, and presence of penumbra, which correlate with reduced hemorrhagic transformation and improved recanalization. Prior intravenous thrombolysis, when eligible, augments outcomes by facilitating faster clot retrieval, though its absence does not preclude benefit in LVO. In M2 occlusions or posterior strokes, success rates are lower but predicted by similar factors, with lower NIHSS and complete first-pass effect enhancing independence.

Risks, Complications, and Limitations

Procedural Adverse Events

Embolus to new territory (ENT), the most frequent procedural complication in mechanical , occurs in approximately 5.2% of cases involving large vessel occlusions, often due to clot fragmentation during device retrieval or manipulation. This event is predicted by terminal carotid or tandem occlusions and increased number of device passes, leading to infarction in previously unaffected vascular beds. In a multicenter registry of over 4,000 patients, ENT was associated with reduced odds of favorable 90-day functional outcome (adjusted OR 0.4) and increased mortality (adjusted OR 1.74), as well as higher rates of symptomatic intracranial hemorrhage. Distal embolization, a related embolic phenomenon, affects 4-6% of procedures and arises from similar mechanical disruption of the thrombus. Vessel perforation, resulting from microwire, microcatheter, or stent-retriever injury to the arterial wall, has an incidence of 0.6-4.9% across series, with 1.69% reported in large registries. It is more common in cases with tandem or terminal carotid occlusions and carries substantial risk, including 40.7% 90-day mortality and elevated symptomatic hemorrhage (adjusted OR 4.73). In the ATTENTION trial of basilar artery occlusion thrombectomy, perforation occurred in 3% of procedures, contributing to an overall 11% rate of device-related complications alongside dissection and embolization. Arterial dissection, typically iatrogenic from catheter or guidewire advancement, manifests in 0.6-3.9% of , predominantly in extracranial cervical vessels (83% of cases). Registry data indicate a 1.46% rate, linked to younger patient age but without significant independent effect on 90-day outcomes when managed conservatively. In a single-center review of 176 cases, dissection occurred in 2%, alongside vasospasm (3%) and other events totaling 11% procedural complications. Overall, major procedural adverse events cluster at 5-11% incidence, influenced by procedural duration, operator experience, and lesion complexity, with embolization and perforation conferring the highest prognostic detriment.

Post-Procedural and Long-Term Concerns

Following successful recanalization, reocclusion of the treated vessel occurs in 2% to 20% of cases within 24 hours, often linked to distal embolization or inadequate antiplatelet therapy, and is associated with poorer functional outcomes and higher mortality. Symptomatic intracranial hemorrhage (sICH) represents a key post-procedural risk, with rates elevated by prolonged procedure times exceeding 60 minutes, which correlate with increased sICH incidence (up to 10-15% in some cohorts) and reduced rates of functional independence at 90 days. Other immediate concerns include groin hematoma from access site complications, vessel perforation leading to subarachnoid hemorrhage, and embolic events causing distal ischemia, necessitating vigilant neuroimaging and hemodynamic monitoring in the first 24-48 hours. Long-term, patients face elevated risks of recurrent ischemic stroke, with cumulative incidence rates of 7.8% at 3 months, 11.0% at 1 year, 19.8% at 5 years, and 26.8% at 10 years, primarily driven by underlying cardioembolic sources or incomplete revascularization. One-year mortality post-thrombectomy averages 30-40% in real-world registries, exceeding rates in non-thrombectomy stroke cohorts due to factors like pre-existing dependency, hyperglycemia, and severe initial deficits, with 365-day mortality reaching 48.6% in comorbid subgroups. Functional outcomes decline over time, with only 20-30% maintaining independence beyond 90 days in elderly patients, compounded by cognitive impairments and dependency; however, thrombectomy survivors exhibit better health-related quality of life trajectories than medical management alone in randomized trial extensions. Secondary prevention challenges, including adherence to dual antiplatelet regimens and statin therapy, are critical to mitigate atherosclerosis-related reevents, though evidence from observational data underscores persistent vascular fragility as a causal factor in late failures.

Controversies and Critical Debates

Indications in Extended or Borderline Cases

Endovascular thrombectomy in extended time windows beyond 6 hours from stroke onset, up to 24 hours, relies on advanced imaging to identify salvageable penumbral tissue, as evidenced by the DAWN trial (published 2018), which demonstrated a 49% rate of functional independence (modified Rankin Scale score ≤2 at 90 days) in thrombectomy-treated patients versus 13% with medical management alone in selected cases with perfusion-core mismatch. Similarly, the DEFUSE 3 trial (2018) reported a number needed to treat of 4 for good outcomes in patients aged 18-90 with target mismatch on perfusion imaging between 6 and 16 hours. These findings underpin American Heart Association/American Stroke Association (AHA/ASA) guidelines recommending thrombectomy for 6-16 hours (Class I, Level A evidence) and 16-24 hours (Class IIa, Level B-R) in eligible anterior circulation large vessel occlusions, yet approximately 70% of late presenters fail mismatch criteria, prompting debates over broader selection using simpler CT-based assessments amid ongoing trials like MR CLEAN-LATE. Critics argue that over-reliance on resource-intensive perfusion imaging may limit access, while proponents emphasize reduced risks of futile procedures. Borderline cases, such as those with low Alberta Stroke Program Early CT Score (ASPECTS 3-5) indicating larger infarct cores, intensify controversies due to elevated procedural risks outweighing benefits in some cohorts; a multicenter study of patients with ASPECTS ≤5 found no improvement in good outcomes (27.4% vs. 25% with best medical therapy) but significantly higher symptomatic intracranial hemorrhage (16.1% vs. 5.6%) and mortality (43.5% vs. 28.9%). Conversely, the HERMES meta-analysis (2016, updated analyses) suggested potential efficacy even for ASPECTS 0-4 (odds ratio 2.15 for favorable reperfusion), particularly with complete recanalization in fewer passes, though randomized evidence remains sparse, with trials like TENSION and RESCUE-Japan LIMIT (ongoing as of 2021) testing thresholds. AHA/ASA 2024 guidance notes limited support for thrombectomy in large cores (e.g., core volume >70 mL or ASPECTS 0-2) beyond 6 hours, highlighting debates on selection to avoid harm in extensive infarcts where hemorrhage risk escalates without guaranteed salvage. Indications in elderly patients (>80 years) or distal occlusions (e.g., ) further complicate decisions, with registry data showing benefits conditional on rapid, successful reperfusion but higher futility rates. Applications beyond 24 hours, termed ultra-extended windows, lack Class I endorsement and spark ethical debates over equipoise; a 2023 meta-analysis of observational studies reported higher functional independence (40% vs. 28%) in thrombectomy versus controls for proximal occlusions >24 hours from last known normal, but with heterogeneous selection and no large randomized trials confirming causality or safety profiles. Proponents advocate case-by-case salvage based on persistent mismatch, yet detractors cite rising hemorrhage incidence and resource strain, underscoring the need for imaging-verified viability to mitigate overtreatment in non-viable tissue.

Operational and Ethical Challenges

Operational challenges in endovascular thrombectomy (EVT) primarily stem from and personnel limitations that hinder timely access, particularly in non-urban settings. Many regions lack dedicated suites capable of 24/7 operation, with shared facilities in countries like and compromising rapid response. Shortages of trained neurointerventionalists further restrict service expansion, as rural and low-resource areas often cannot sustain round-the-clock coverage. Logistical delays exacerbate these issues, including prehospital inaccuracies—prehospital large vessel occlusion scales achieve only 50-70% specificity—and inter-hospital transfers, which affect 27.3% of patients and contribute to treatment times exceeding optimal windows. , 33% of the population resides more than from an EVT center, with rural patients reaching capable facilities at rates of just 27.7% compared to 69.5% in urban areas. Each 10-minute delay in reduces disability-free lifetime by approximately 40 days. Access disparities compound operational bottlenecks, influenced by geography, socioeconomic status, and ethnicity. In low- and middle-income countries, EVT reaches only urban minorities due to high out-of-pocket costs (up to 90% in ) and annual healthcare expenditures as low as $50-300 USD per capita. Even in high-income settings like the , many regions limit EVT to daytime hours, while U.S. ethnic minorities such as and patients experience lower utilization rates. Resource constraints persist despite evidence of long-term cost savings; only 8.4% of eligible acute ischemic patients received mechanical thrombectomy in 2018 across 176 U.S. centers, reflecting insufficient high-volume facilities and . Expansion efforts, such as increasing EVT-capable centers by 10%, could extend 30-minute access to 10% more residents but require addressing staffing and low-volume center risks that may worsen outcomes. Ethical challenges in EVT center on , decisional capacity, and resource stewardship amid acute time pressures. Acute ischemic frequently impairs patients' understanding, appreciation, reasoning, and choice, rendering traditional infeasible; presumption of consent is thus justified for eligible large vessel occlusions up to 24 hours post-onset when or directives are unavailable, given the procedure's potential to avert severe . decision-making via advance directives or next-of-kin serves as an alternative, with post-procedure disclosure to patients or representatives. Aligning EVT with patients' goals of care demands multidisciplinary assessment of its —restoring function versus prolonging life—and uncertainties in outcomes, particularly for those with comorbidities or borderline eligibility. Resource allocation raises justice concerns, as EVT's cost-effectiveness—yielding societal savings of $1.7 billion across for 267,514 cases in 2017 while generating 101,327 quality-adjusted life years—contrasts with implementation barriers that perpetuate inequities. In resource-limited settings, prioritizing high-benefit cases over futile interventions requires explicit proportionality assessments, avoiding overuse driven by procedural incentives or underuse due to geographic barriers. Ethical frameworks emphasize evidence-based values and team input to ensure goal-concordant care, mitigating risks of overtreatment in low-yield scenarios or undertreatment in underserved populations.

Recent Advances

Technological and Procedural Innovations

Recent advancements in thrombectomy devices have focused on enhancing clot retrieval efficiency and reducing procedural times through optimized retriever designs and aspiration systems. Next-generation retrievers, such as the device featuring integrated "drop zones" for internal clot trapping, have demonstrated improved efficacy in preclinical and early clinical evaluations by minimizing fragment embolization during retrieval. Larger-diameter variants, like the Solitaire 6 × 40 mm retriever, have shown superior first-pass recanalization rates and functional outcomes compared to smaller 4 × 40 mm models in mechanical thrombectomy for large vessel occlusions, with comparable safety profiles in a 2025 study. Aspiration catheters have evolved with innovations like the Zoom Stroke System, which incorporates asymmetric tip designs for better navigation and clot engagement across a range of sizes (0.035–0.088 inches); the Imperative Trial in 2025 reported median reperfusion times of 19 minutes from groin puncture to modified in (mTICI) 2b/3 scores in 211 patients, with low rates of vessel injury (0.5%) and symptomatic (0.9%). Procedural techniques have incorporated combination approaches to maximize recanalization while minimizing passes. The Continuous Dual Aspiration Technique (CDAT), utilizing dual-port catheters like the Zoom DuoPort connected to a single vacuum source, sustains consistent aspiration pressure and has achieved rapid TICI 3 reperfusion in under 10 minutes in reported cases, reducing distal emboli compared to single-catheter methods. Contact aspiration alone has demonstrated advantages over combined aspiration plus stent retriever for M1 and M2 occlusions in a 2025 analysis, offering shorter procedure times and equivalent or better without increased complications. Balloon guide catheters, when paired with stent retrievers, further optimize outcomes by controlling antegrade flow and decreasing distal risks, as evidenced in post-2020 meta-analyses showing improved reperfusion rates. Emerging integration of robotic systems and AI-guided navigation promises enhanced precision for distal occlusions, though clinical data remain preliminary as of 2025.

Expanded Research Horizons

Ongoing investigations seek to broaden mechanical thrombectomy's applicability to medium vessel occlusions (MeVO) and distal vessel occlusions (DVO), where initial randomized trials such as ESCAPE-MeVO and DISTAL have not demonstrated functional outcome benefits over best medical therapy, with higher rates of symptomatic (sICH) observed (5.4% vs. 2.2% in ESCAPE-MeVO; 5.9% vs. 2.6% in DISTAL). These challenges stem from lower reperfusion rates (71.7%-77% vs. >85% in large vessel occlusion trials), anatomical difficulties in navigating smaller vessels, and inclusion of older patients with baseline disabilities. Nevertheless, ongoing trials including DISTALS, STEP, ORIENTAL-MeVO, and aim to refine patient selection criteria, incorporate novel outcome measures like NIHSS score changes, and test aspiration-focused techniques to potentially establish . Research also explores thrombectomy in atypical stroke presentations, such as mild strokes with low Stroke Scale (NIHSS) scores (0-5) despite large vessel occlusion, through trials like MOSTE and ENDOLOW, which evaluate whether intervention improves outcomes beyond medical management alone. For patients with large ischemic cores (ASPECTS 3-5), trials including RESCUE-Japan LIMIT, SELECT-2, and ANGEL-ASPECTS have provided evidence supporting thrombectomy's role in reducing mortality and enhancing independence, prompting further studies on imaging thresholds like collateral scores from CT angiography. Extended time windows beyond 24 hours from last known well remain under scrutiny, with meta-analyses indicating uncertain benefits and risks, as seen in evaluations pooling data from selective cases using advanced imaging. Technological frontiers emphasize integration of (AI) for automated imaging analysis, patient selection, and procedural planning to address disparities in access and optimize clot retrieval via advanced aspiration devices or balloon guide catheters. and AI-guided systems promise enhanced precision in navigation and decision-making, potentially reducing operator variability and enabling remote or low-resource interventions, though ethical guidelines and training protocols require development. Complementary research investigates adjunctive neuroprotective strategies, such as hypothermia-inducing agents or antioxidants, in combination with thrombectomy, alongside rehabilitation innovations like brain-computer interfaces. For tandem occlusions involving cervical carotid , trials like EASI-TOC and TITAN continue to clarify optimal sequencing of stenting and thrombectomy. These efforts highlight gaps in pre-hospital pathways and management of pre-stroke dependent patients ( 3-5), necessitating randomized data to balance potential gains against procedural risks.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK562154/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10414072/
  3. https://www.ncbi.nlm.nih.gov/books/NBK532535/
  4. https://www.ahajournals.org/doi/10.1161/STROKEAHA.115.010863
  5. https://evtoday.com/articles/2016-feb/mechanical-thrombectomy-trials-in-acute-ischemic-stroke
  6. https://www.sciencedirect.com/science/article/pii/S0735109715067042
  7. https://www.nejm.org/doi/full/10.1056/NEJMoa2214403
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8458081/
  9. https://pubmed.ncbi.nlm.nih.gov/34511142/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC7224978/
  11. https://my.clevelandclinic.org/health/treatments/22897-thrombectomy
  12. https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.117.005362
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC3613201/
  14. https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034754
  15. https://www.ahajournals.org/doi/10.1161/strokeaha.108.544957
  16. https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26802
  17. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6FFC274D55FF907C7045480658C9CB14/S0317167124002920a.pdf/look_back_on_the_history_of_cerebral_revascularization_for_acute_ischemic_stroke_a_neurosurgeons_perspective.pdf
  18. https://journals.lww.com/neur/fulltext/2021/69030/microsurgical_embolectomy_in_the_current_era_of.5.aspx
  19. https://www.cambridge.org/core/product/6FFC274D55FF907C7045480658C9CB14
  20. https://thejns.org/focus/view/journals/neurosurg-focus/46/2/article-pE2.pdf
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4233417/
  22. https://www.nejm.org/doi/full/10.1056/NEJMoa1411587
  23. https://www.nejm.org/doi/full/10.1056/NEJMoa1612136
  24. https://www.nejm.org/doi/full/10.1056/NEJMoa1414905
  25. https://www.nejm.org/doi/full/10.1056/NEJMoa1415061
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10152824/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC10399505/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7820689/
  29. https://pubmed.ncbi.nlm.nih.gov/32532857/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6372897/
  31. https://evtoday.com/articles/2016-feb/adapt-a-direct-aspiration-first-pass-technique
  32. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2021.695085/full
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC10546392/
  34. https://jnis.bmj.com/content/10/Suppl_2/A124.2
  35. https://www.ajnr.org/content/early/2016/06/02/ajnr.A4840
  36. https://www.ahajournals.org/doi/10.1161/strokeaha.116.016149
  37. https://www.ahajournals.org/doi/10.1161/SVIN.122.000689
  38. https://pubmed.ncbi.nlm.nih.gov/38159607/
  39. https://jnis.bmj.com/content/12/4/396
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC10934276/
  41. https://www.ajnr.org/content/43/4/568
  42. https://jamanetwork.com/journals/jama/fullarticle/2784507
  43. https://www.ahajournals.org/doi/10.1161/SVIN.123.001004
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC10657729/
  45. https://www.ahajournals.org/doi/10.1161/SVIN.124.001563
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC7963712/
  47. https://www.ahajournals.org/doi/10.1161/STR.0000000000000211
  48. https://www.ahajournals.org/doi/10.1161/SVIN.124.001581
  49. https://jnis.bmj.com/content/11/3/215
  50. https://karger.com/ced/article/doi/10.1159/000546720/929609/Long-Term-Outcomes-of-Endovascular-Treatment
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC5933543/
  52. https://www.jvascsurg.org/article/S0741-5214%2823%2902196-1/fulltext
  53. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2020.557420/epub
  54. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001251
  55. https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.122.012166
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC12171853/
  57. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.072364
  58. https://pubs.rsna.org/doi/full/10.1148/rg.220026
  59. https://pubmed.ncbi.nlm.nih.gov/39515614/
  60. https://eurointervention.pcronline.com/article/percutaneous-treatment-options-for-acute-pulmonary-embolism-a-clinical-consensus-statement-by-the-esc-working-group-on-pulmonary-circulation-and-right-ventricular-function-and-the-european-association-of-percutaneous-cardiovascular-interventions
  61. https://www.nejm.org/doi/full/10.1056/NEJMoa1414792
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4162915/
  63. https://www.nejm.org/doi/full/10.1056/NEJMoa1713973
  64. https://www.neurology.org/doi/10.1212/WNL.0000000000212131
  65. https://pubmed.ncbi.nlm.nih.gov/34785611/
  66. https://pubmed.ncbi.nlm.nih.gov/34766505/
  67. https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034960
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC4160889/
  69. https://pubmed.ncbi.nlm.nih.gov/35636948/
  70. https://jnis.bmj.com/content/14/11/1051
  71. https://www.strokejournal.org/article/S1052-3057%2825%2900090-4/fulltext
  72. https://www.nature.com/articles/s41598-023-45232-x
  73. https://www.ahajournals.org/doi/10.1161/SVIN.123.001017
  74. https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.034865
  75. https://www.nejm.org/doi/full/10.1056/NEJMoa2207576
  76. https://pubmed.ncbi.nlm.nih.gov/24668181/
  77. https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.026228
  78. https://pubmed.ncbi.nlm.nih.gov/30819354/
  79. https://jnis.bmj.com/content/13/10/912
  80. https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.038155
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC11008522/
  82. https://www.sciencedirect.com/science/article/pii/S1052305722005262
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC10832147/
  84. https://pubmed.ncbi.nlm.nih.gov/41108333/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC9326078/
  86. https://www.nejm.org/doi/full/10.1056/NEJMoa1706442
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC7970189/
  88. https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.033101
  89. https://www.ahajournals.org/doi/10.1161/STR.0000000000000481
  90. https://journals.sagepub.com/doi/10.1177/1756286421998905
  91. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804474
  92. https://www.ahajournals.org/doi/10.1161/STROKEAHA.124.045889
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC8829477/
  94. https://www.neurology.org/doi/10.1212/WNL.0000000000013040
  95. https://pubmed.ncbi.nlm.nih.gov/38364896/
  96. https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.031027
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC12479453/
  98. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1618737/full
  99. https://evtoday.com/articles/2025-june/embracing-new-technologies-and-techniques-for-mechanical-thrombectomy
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC12223926/
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC11872241/
  102. https://www.frontiersin.org/research-topics/72412/advances-in-mechanical-thrombectomy-devices-for-acute-ischemic-stroke-from-first-generation-to-next-generation-innovation
  103. https://www.ahajournals.org/doi/10.1161/SVIN.125.001785
Add your contribution
Related Hubs
User Avatar
No comments yet.